Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
1.550
+0.050 (3.33%)
At close: Apr 23, 2025, 4:00 PM
1.520
-0.030 (-1.94%)
Pre-market: Apr 24, 2025, 7:38 AM EDT
Company Description
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications.
Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018.
Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.
Outlook Therapeutics, Inc.
| Country | United States |
| Founded | 2010 |
| IPO Date | May 13, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Lawrence Kenyon |
Contact Details
Address: 111 S. Wood Avenue, Unit #100 Iselin, New Jersey 08830 United States | |
| Phone | 609 619 3990 |
| Website | outlooktherapeutics.com |
Stock Details
| Ticker Symbol | OTLK |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001649989 |
| CUSIP Number | 69012T206 |
| ISIN Number | US69012T3059 |
| Employer ID | 38-3982704 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Lawrence A. Kenyon CPA | EVice President, Chief Financial Officer, Interim Chief Executive Officer, Treasurer, Secretary and Director |
| Jeffrey Evanson | Chief Commercial Officer |
| Joel Prieve | Senior Vice President of Licensing and M&A |
| Dr. Surendra Sharma M.D. | Senior Vice President of Medical Affairs |
| Dr. Jennifer M. Kissner Ph.D. | Senior Vice President of Clinical Development and Regulatory Affairs |
| Jedd Comiskey | Senior Vice President - Head of Europe |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2025 | 8-K | Current Report |
| Apr 10, 2025 | SCHEDULE 13G/A | Filing |
| Apr 8, 2025 | 8-K | Current Report |
| Mar 28, 2025 | EFFECT | Notice of Effectiveness |
| Mar 28, 2025 | 424B3 | Prospectus |
| Mar 20, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 14, 2025 | 8-K | Current Report |
| Mar 12, 2025 | SCHEDULE 13D/A | Filing |
| Mar 7, 2025 | EFFECT | Notice of Effectiveness |
| Mar 7, 2025 | 424B3 | Prospectus |